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Abstract
This work aims at identifying a set of humoral immunologic parameters that improve prediction of the activation process in
HIV patients. Starting from the well-known impact of humoral immunity in HIV infection, there is still a lack of knowledge in
defining the role of the modulation of functional activity and titers of serum antibodies from early stage of infection to the
development of AIDS. We propose an integrated approach that combines humoral and clinical parameters in defining the
host immunity, implementing algorithms associated with virus control. A number of humoral parameters were
simultaneously evaluated in a whole range of serum samples from HIV-positive patients. This issue has been afforded
accounting for estimation problems typically related to ‘‘feasibility’’ studies where small sample size in each group and large
number of parameters are jointly estimated. We used nonparametric statistical procedures to identify biomarkers in our
study which included 42 subjects stratified on five different stages of HIV infection, i.e., Elite Controllers (EC), Long Term Non
Progressors (LTNP), HAART, AIDS and Acute Infection (AI). The main goal of the paper is to illustrate a novel profiling
method for helping to design a further confirmatory study. A set of seventeen different HIV-specific blood humoral factors
were analyzed in all subjects, i.e. IgG and IgA to gp120IIIB, to gp120Bal, to whole gp41, to P1 and T20 gp41 epitopes of the
MPER-HR2 region, to QARILAV gp41 epitope of the HR1 region and to CCR5; neutralization activity against five different
virus strains and ADCC were also evaluated. Patients were selected on the basis of CD4 cell counts, HIV/RNA and clinical
status. The Classification and Regression Trees (CART) approach has been used to uncover specific patterns of humoral
parameters in different stages of HIV disease. Virus neutralization of primary virus strains and antibodies to gp41 were
required to classify patients, suggesting that clinical profiles strongly rely on functional activity against HIV.
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Introduction
Host humoral immunity is differently involved in fighting HIV
infection during progression from first virus contact to overt
infection, including evolution from acute to chronic course.
Antibodies are key players and take part in different aspects of
host-virus interaction, especially those directed at the HIV-1
envelope glycoprotein subunits, gp120 and gp41 that interferes
with the initial entry events. However, due to high HIV-1
envelope sequence natural variability, generation of high-titer
neutralizing antibodies has been proven difficult. Generically,
high-titer of serum neutralizing antibodies have been considered a
correlate of HIV protection, although they only appear after
months or years of infection, possible upon a deep antigen
stimulation sustained by high virus load [1].
Hence, serum antibodies raised against HIV-1 envelope
proteins during acute infection are usually ineffective to prevent
the establishment of infection, their selective pressure does not
control–but can even sustain–autologous virus escape [2].
Subsequent waves of antibodies targeting specific, functional
epitopes maintain virus drift through their increased affinity and
keen targeting [3]. Antibodies to conserved, neutralizing domains
(e.g., the gp120 carbohydrate, MPER) develop heterogeneously in
chronic infection, and are not always neutralizing, despite specific
of neutralizing motifs. It suggests that generation of neutralizing
antibodies is controlled by many factors, such as host genetics,
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modes of antigen exposure, antibody affinity maturation, and
immune tolerance [3]. Other serum humoral responses, bridging
innate and adaptive immunity, such as those mediated by binding,
non-neutralizing antibodies through Fc receptor, complement
cascade and effector killer cells, were also observed in acute
infection [3]. Some of these, such as ADCC (Antibody-Dependent
Cellular Cytoxicity) and ADCVI (Antibody-Dependent Cell-
mediated Virus Inhibition), were found more significant than
virus neutralization in protection, being associated with reduced
viremia and better virus control. Indeed, sera from HIV
controllers showed a significantly higher ADCC activity, high-
lighting the specific role of this mechanism in long-term HIV
control [4,5].
In this study we aim at providing a multivariate nonparametric
analysis to combine information from serum envelope-specific
antibodies targeting key HIV epitopes, ADCC and infectivity
reduction against a panel of viruses. These parameters are
measured in various groups of HIV-positive patients at different
stages of infection. Moreover, as anti-CCR5 antibodies have been
associated to protection, we checked for such antibodies in all
subjects, to establish whether such antibodies could represent a
marker of resistance to HIV infection or progression of the disease
[6,7].
The classification and regression tree methodology (CART)
developed by Breiman et al. [8] has been applied to use a
combined information derived from the whole set if parameters for
identifying possible biomarkers. CART is a non-parametric
technique for partitioning a population/sample into subgroups.
Actually it operates a selection of the explanatory variable, useful
to construct the tree, on the basis of their capacity in identifying
the most homogeneous subgroups.
This strategy allowed to define profiles of antibody reactivity
specific to each group and identify specific ‘‘humoral signatures’’
which may not only have diagnostic relevance, but also identify
possible protective parameters by new combinations of humoral
factors.
Thus, the paper focuses on the search for a novel biomarker
combination that might be assessed as predictive on confirmative
larger studies for the evolution of disease in HIV patients.
Considering a biomarker panel with respect to the single
biomarker improves the diagnosis and may serve as an early
warning system of risk for future adverse AIDS outcomes. This
goal cannot be achieved by common ROC curve approach, that
searches for the greatest separation of two probability curves,
leading to the likelihood of distinguishing a sick patient from
healthy one based on a unique trait only. Thus ROC method can
be used for comparisons only to decide whether one marker allows
for better screening between diseased and not diseased subjects
with respect to another marker.
Conversely, we constructed a parameters panel on the basis of
different parameters combination.
Results
Patients and Experimental Design
Forty-two serum samples from HIV-infected patients at
different clinical stages (10 AI, 7 AIDS, 8 EC, 7 HAART+, 10
LTNP) were examined (Table 1). Patients in AI and HAART+
subgroups received appropriate therapy. AI subjects were evalu-
ated both before and after 4–8 months of treatment. All humoral
parameters studied were evaluated in parallel with CD4+ T cell
count and viral RNA load (Table 1). Eighteen humoral parameters
concerning specific IgG and IgA profiles, as well as functional
antibody assays were performed in all samples, for a total of 23
individual parameters (Table 2), treated as continuous or as
categorical variables; twenty-three endpoints actually underwent
statistical analyses.
Humoral Parameters
The study focused total IgG and IgA, and HIV-specific IgG and
IgA to gp120Bal (R5 strain), gp120IIIB (X4 strain), gp41, three
different gp41 epitopes (QARILAV within HR1, T20 and P1 both
in the MPER domain within HR2, already described as target of
neutralizing antibodies in humans) and finally, anti-self antibodies
to CCR5 coreceptor, which were previously found in LTNP
Table 2 [6,7,9–11].
Figure 1, reports the distribution of seven antibodies, namely
IgG and IgA to specific gp41 epitopes and to CCR5 coreceptor.
These measurments are categorical. Their descriptive analysis
revealed that:
N Both IgA-CCR5 and IgG-CCR5 were uniquely observed in
some EC and LTNP patients.
N IgG-QARILAV were mainly found in AIDS patients, but not
in AI group. No such IgA were isolated in any group.
N IgG-P1 peptide were found in all groups but EC, correspond-
ing IgA in all groups except EC and AIDS.
N IgG-T20 were observed in all groups, such IgA were only in
LTNP and in AIDS patients.
Continuous measurements were provided on total immuno-
globulins isotypes and specific IgA and IgG to whole gp120 and
gp41 (see graphical representation in Figure 2, panel A).
The corresponding ‘‘ratio variables’’ were obtained by normal-
izing raw values of continuous variables over the total amount of
the immune response (see also Statistics section).
With respect to the distributions of ratio variables (Figure 2,
panel B), Gp41 showed higher variability in IgA than IgG (except
Table 1. Characteristic, clinical status of the studied population.
N6 Risk factor Mean Age (Range) Sex Therapy Mean HIV RNA (Range) Mean CD4 (Range)
AI 10 HE, HO 31 (17–49) 6M, 4F NO 88450 (,37–190000) 621 (204–1069)
HAART 7 HE, HO 42 (32–61) 9M, 1F YEStn:a ,37 738 (517–2184)
AIDS 7 HO, IVDU 37 (33–46) 5M, 2F NO 73637 (21079–440000) 226 (141–235)
EC 8 HE, HO, IVDU 51 (34–67) 4M, 4F NO ,37 1082 (511–1880)
LTNP 10 HE, HO, IVDU, TR 49 (43–71) 7M, 3F NO 2680 (,37–11000) 821 (513–1515)
In the ‘‘Risk factor’’ column, HE is an abbreviation for ‘‘Heterosexual’’, HO for ‘‘Homosexual’’ and TR for ‘‘Transfusion’’, while IVDU stands for IntraVenous Drug Users.
12NRTI, 3NRTI, NNRTI+IP,3NRTI+IP, 2NRTI+2IP.
doi:10.1371/journal.pone.0058768.t001
Humoral Immunity in HIV Infection by CART Analysis
PLOS ONE | www.plosone.org 2 March 2013 | Volume 8 | Issue 3 | e58768
for LTNP patients). Distributions of ratio variables, both IgA-
gp120IIIB and IgG-gp120IIIB, when scaled by the respective total
response, had similar behavior both in terms of location and
dispersion, especially in AI patients. IgA-gp120IIIB showed higher
dispersion that IgG-gp120IIIB in HAART patients. IgA-gp120Bal
and IgG-gp120Bal showed a similar behavior in all patents’ groups
(Figure 2, panel B).
Antibody Mediated Functional Activities
Neutralizing potential of all sera was assayed on six virus strains;
two methods with two different cell lines as target cells, TZM-bl
and U87, were used, to enhance assay sensitivity. Distributions of
viruses are shown in Figure 3.
SOS140 was used to infect U87 cell line, the other viruses
including SF162 (lab strain), three clade B (QH0692, PVO and
AC10) and a clade C (ZM214) primary isolates, were used to infect
TZM.bl cells. HC (healthy controls) pooled sera were used as
negative control and TRIMAB monoclonal antibody was used as
positive control.
Neutralization activity was poor in AI and in EC groups and
remarkable in LTNP and AIDS patients in the four primary
viruses (QH0692, PVO, AC10 and ZM214), suggesting it could be
induced and enhanced by long-lasting exposure to viral antigens
(Figure 3).
Conversely, ADCC activity was observed in patients exposed to
very low levels of circulating viral antigens, such as AI, EC, LTNP
and in the group receiving HAART, while it was very low in AIDS
patients; hence, a low amount of viral load could be crucial to
induce and maintain this type of humoral response over time:
strikingly, AI and EC groups showed high ADCC vs poor
neutralizing activity (Figure 3).
Classification Trees
The joint effect of endpoints in classifying patients into
clinically-important groups was assessed through Classification
and Regression Tree analysis (CART) [8]. To this purpose, all the
humoral parameters, the virological endpoints, and patients
groups were included in the analysis. Figure 4 shows resulting
CARTs and decision rules, displayed in a simplified version;
numerical values correspond to antibody dilutions or to neutral-
izing titer, respectively.
CART on binding antibodies (before pruning). Two out
of 13 variables entered in the model were selected to discriminate/
classify patients’ groups. Only information from IgG-types
antibodies were required to classify patients (Figure 4, A). The
ratio-IgG-gp120Bal (when ratio-IgG-gp120Bal,303) allowed to
correctly classify 70% AI patients; using the ratio-IgG-gp41 (when
ratio-IgG-gp41$394), 100% LTNP were correctly classified.
When ratio-IgG-gp41,394, 75% EC, 71.4% AIDS and 71.4%
HAART+ patients were classified, respectively. We concluded that
AIDS, HAART+ and EC patients shared a similar pattern,
completely different from LTNP patients.
CART on functional activities (before pruning). Three
out of 7 variables entered in the model were selected to
discriminate/classify patients’ groups. SF162 neutralization clas-
sified all AI patients (Figure 4, B); information on QH0692
identified 85.7% HAART+ patients. AC10 data discriminated
85.7% AIDS patients (when AC10$96) and 70% LTNP patients
(when AC10,96).
CART on antibody mediated binding and functional
activities (before pruning). Three out of 20 variables entered
in the model were selected to discriminate/classify patients’
groups. Notably, two out of three branches of this latter tree
resulted super-imposable to the previous CART tree, where only
virus data were used (Figure 4, C). SF162 data classified AI
patients; information on QH0692 also identified 85.7% HAART+
patients (when QH0692,30). The binary variable IgG-QAR-
ILAV, distinguished 71.4% AIDS patients (when IgG-QARI-
LAV?0) and 90% LTNP patients (when IgG-QARILAV=0).
CART trees were implemented using R software [12] (package
rpart, see http://www.R-project.org). Default ‘‘cost complexity’’
factor cp= 0.01 was chosen.
To determine whether trees were appropriate or if some of the
branches needed to be subjected to pruning, thus avoiding
overfitting and controlling the size of the decision trees, we have
examined the cross-validated error results (‘‘xerror’’, see Table S1
in File S1), and we have selected the ‘‘complexity parameter’’ (cp
parameter, see Figure S1 in File S1) associated with the smallest
cross-validated error; then we placed it into the function ‘‘prune’’
to prune the tree. Resulting trees after pruning are shown in
Figure 5 and described below.
CART on binding antibodies (after pruning). One out of
13 variables entered in the model were selected to discriminate/
Table 2. Parameters used in the study.
Humoral parameters
Viruses used for the
neutralization
Protein Tot. Region Isotype Viruses Clade Tropism Target cells
CCR5 ECL1tn:b IgG-IgA SOS 140 Lab Strain B R5 U87
HR2-gp41 P1-HR2tn:c IgG-IgA SF162 Lab Strain B R5 TZMbl
HR2-gp41 T20-HR2tn:d IgG-IgA QH0692 Primary B R5 TZMbl
HR1-gp41 HR1tn:e IgG-IgA PVO Primary B R5 TZMbl
gp41 Consensus B IgG-IgA AC10 Primary B R5 TZMbl
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classify patients’ groups. Only information from IgG-gp120Bal
antibody was maintained after pruning. Hence when ratio-IgG-
gp120Bal,303 70% AI patients were correctly classified, when
ratio-IgG-gp120Bal$303, 100% LTNP were correctly classified
(Figure 5, A).
CART on functional activities (after pruning). Two out of
7 variables entered in the model were selected to discriminate/
classify patients’ groups (Figure 5, B). SF162 neutralization
classified all AI patients. QH0692 data discriminated 85.7%
HAART+ patients (when QH0692,30) and 100% LTNP patients
(when QH0692$30).
CART on antibodies mediated binding and functional
activities (after pruning). Two out of the 20 variables entered
in the model were selected to discriminate/classify patients’ groups
(Figure 5, C). SF162 data classified AI patients; information on
QH0692 also identified 85.7% HAART+ patients (when
Figure 1. Distribution of binding antibodies in all studied groups. Graphical representation of non-continuous variables, i.e. parameters
found in some subjects or groups only. Seven variables, including IgG and IgA to specific gp41 epitopes (P1, T20, QARILAV) and antibodies to CCR5
coreceptor. First bar in each pair shows proportion of values found equal to 0 in the analysis, the second illustrates values different from 0. Chi-square
association test between categorical variables only found a significant association between IgGT20 and IgGP1 (p-value = 0.001).
doi:10.1371/journal.pone.0058768.g001
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QH0692,30) and 100% LTNP patients (when QH0692$30).
After pruning, the last two trees were found to be equal, because
only information on virus was selected to classify patients.
In general, the pruning procedure is applied to avoid overfitting
the data. However, in our data set, only few variables were
selected in the ‘‘growing phase’’ of the tree. Then during the
‘‘pruning phase’’ only the last node was deleted and, as a result,
there was an increase the misclassification error. Hence, in our
particular case, pruning phase was not really effective and tree
obtained before pruning are more informative.
Finally, we faced the validation issue. Since small sample size
represents a difficult feature to afford a cross-validation procedure,
we evaluated the performance of the tree in terms of misclassi-
fication rate by bootstrapping 1000 trees based on the same
covariates of our analyses (ratio of antibodies, viruses and
combination of both). This procedure led to classifying correctly
70% of the observation for each tree, that can be considered a
robust proportion once related to the initial sample composition.
Discussion
The definition of key protective factors conferring optimal
in vivo protection is still debated. At our knowledge, this is the first
study where a number of humoral parameters were simultaneously
evaluated in a whole range of serum samples from HIV-positive
patients. Despite the small sample size, due to the clear definition
of the research objective, this study can be considered as ‘‘pilot’’,
and design new diagnostic strategies for larger studies. We assessed
antibodies to specific HIV epitopes, to CCR5, virus neutralization
and ADCC, and specific statistical tools were applied, aimed at
defining specific``humoral signatures biomarkers characteristics of
each clinical status. Notably, all parameters were simultaneously
tested, using the same methods and the same source of reagents to
minimize variability, which is a relevant issue in HIV research,
when immune correlates of protection have to be uniquely
identified.
Since the analysis was aimed at investigating variables
combinations in defining diagnostic categories, a multivariate
approach was chosen. While standard ANOVA approach
examines covariates effect one by one, the use of CART procedure
allowed for analyzing multiple humoral parameters, classified as
categorical or continuous, for the identification of antibodies
patterns. Correlation of particular immune response profiles and
clinical stages of HIV infection suggests novel immunopathway(s)
that could be exploited to improve immune control of HIV.
By means of Trees representation, it can be easily visualized that
IgA and IgG antibodies exhibited different, sometimes opposite,
patterns throughout patients groups. AI, AIDS and EC groups
showed similar patterns on IgA total response; IgG total response
showed high variability, especially in AI, EC and LTNP group.
Antibodies to CCR5 were only observed in some patients
controlling the infection (EC and LTNP), suggesting that they
could be elicited late in the course of infection and that a low-dose
antigen exposure could allow their maturation. Interestingly, anti-
MPER antibodies showed different patterns in LTNP and EC
groups, suggesting that their generation might depend on the
presence of circulating virus. Moreover, IgG-T20 and IgG-P1
were different in all groups, suggesting that humoral responses
differently addressed 2F5 and other MPER epitopes, variously
assorted within partly overlapping T20 and P1 sequences (see
Tables 1–2). In fact, P1 (aa 650–684) is a 35 amino acid long
peptide, which adopts a 3D conformation that could improve
recognition by antibodies binding conformational epitopes; both
lipid environment and pH are critical for determining physiolog-
Figure 2. Graphical representations of humoral parameters. Panel A shows antibody concentrations, Panel B reports ratio of antibodies to
total IgG or IgA.
doi:10.1371/journal.pone.0058768.g002
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Figure 3. Antibodies functional activities including neutralization and ADCC in the study population. Neutralization profiles obtained
with six different viruses in two assays which use U87 or TZM.bl cell lines as target cells are shown. SOS140 was used to infect U87 cell line, the other
viruses including SF162 (lab strain), three clade B (QH0692, PVO and AC10) and a clade C (ZM214) viruses were used to infect TZM.bl. HC (healthy
controls) pooled sera were used as negative control and TRIMAB monoclonal antibody mix was used as positive control. The values are expressed as
IC50 (serum dilution 1/n for all samples or mg/mL for TRIMAB leading 50% of infectivity reduction). The last panel, in the middle, shows ADCC activity
by all five groups of HIV seropositive subjects. HC (healthy controls) pooled sera and 89.6 IgG were used as negative and positive controls,
respectively. The values are expressed as titers.
doi:10.1371/journal.pone.0058768.g003
Figure 4. Classification trees resulting from CART analysis, performed with binding antibodies (A), functional activities data data
(B) or antibody mediated binding and functional activities (C). Numbers inside grey squares indicate the discrimination level and are
expressed as dilution 1/n.
doi:10.1371/journal.pone.0058768.g004
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ical solution structure of P1 epitopes without altering the native
3D-structure of MPER [13]. P1 contains a bent in its C-terminal
region, just placed at the level of the 4E10 epitope; furthermore,
2F5 and 4E10 IgG recognize P1 better than their nominal
epitopes ELDKWA [14] and NWFDIT (unpublished results). In
contrast, T20 (aa 638–673) has a shorter C-terminus compared to
P1 (Tables 1–2), it therefore does not contain the hydrophobic
region that participates in the structure of the W-rich region
present in P1. In addition, T20 does not contain the 4E10 epitope
and would lack proper 3D structure [15,16].
Therefore it would be poorly recognized by antibodies against
conformational epitopes, i.e., the opposite condition observed with
P1 peptide. IgG-QARILAV antibodies appeared in later stages of
infection, were absent in AI and had the highest titers in the AIDS
group. This fact may imply very-low dose antigens, or defective
virions could have triggered such antibody production. Interest-
ingly, virus particles generated in the late phase of the infection,
including AIDS, could differ from those sustaining early infection;
this finding was usually observed in isolates undergoing many
subsequent infection cycles in vitro, and therefore might explain
the lack of such antibodies in AI [17]. A key point emerging from
CART analysis is that data about specific IgG-gp41 and viruses
were both required to define patients’ status (Figure 4, C). The
protective role of anti-gp120 antibodies, taken as a whole, agrees
with previous studies, where gp120-binding antibodies were
associated to virus control via ADCC and ADCVI, with different
antibody subsets mediating virus neutralization in terms of
specificity and of timing of generation [5,18,19]. Notably, these
studies did not take into account specific binding properties and
timing of generation of antibody subsets to gp120 and gp41,
neither IgA contribution was evaluated. Antigen exposure was
required to sustain neutralization activity, as it was found limited
or absent in AI and in EC groups but high in LTNP, HAART and
AIDS. SF162 (lab strain B-R5) was the most sensitive strain in
neutralization assays; neutralizing titers to other clade B strains
were by far lower (e.g. titers ,200 vs PVO), suggesting that each
virus within the panel had a different sensitivity to neutralization
even within the same clade. This is also true for clade C ZM214
strain, which was neutralized at very low titers (titers ,50),
probably due to the fact that each patients’ group can display a
different neutralizing potential towards a given virus strain. This
might depend on the exposure to clade-specific strains, but also on
modes and duration of antigen exposure. In fact, in some studies,
LTNP showed very high neutralizing titers to different virus
strains, while EC patients only achieved poor or no neutralizing
activity at all [4,20,21]. Differently from neutralizing antibodies,
ADCC was observed since early stages of infection while declining
in AIDS, suggesting it plays a role in controlling HIV in AI and in
later stages of infection. The tree based on virus neutralization
data achieved a better group classification (Figure 4, B); strikingly,
it was partly identical to that generated with both virus and
antibody data, thus confirming that functional ability to neutralize
viruses correlated more accurately with clinical classification of
patients than the presence of specific antibody subsets, or with
antibody proportion over total immunoglobulin content. Although
we relied on this statistical technique due to the numerous
advantages listed above and in the Statistics Section, however we
are aware that CART methods suffer a big limitation since they
split only by one variable. This may imply that if the data set has
more complex structure then CART may not catch it correctly.
Indeed, key points emerging from CART analysis were the
following:
N gp41 plays a crucial role in determining a stage-specific
signature, as IgG to whole gp41 or to its QARILAV epitope
appeared in both ‘‘binding antibodies only’’ and in ‘‘com-
bined’’ trees (Figure 4, A and C);
N virus neutralization, i.e. functional activity, was more predic-
tive than antibody binding in defining clinical profiling; after
pruning the tree, neutralization of two virus strain (a lab and a
primary strain) were retained in the model in ‘‘functional
activities only’’ and especially in ‘‘combined’’ tree, while the
other humoral parameters were fully excluded (compare
Figure 4, B and C, vs Figure 5, B and C);
N ADCC, albeit observed in some clinical groups, was less
significant than neutralization in terms of patients classifica-
tion;
N antibodies to gp41 and neutralizing activity could offer a
reliable tool in clinical stratification of small-medium sized
panels of patients;
N CART classification of parameters did not select immune
parameters according to their potential in terms of immune
protection, but only by a clinical point of view.
Thus, we recommend this methodology as suitable to provide
diagnostics guidelines in pilot studies.
Small studies with all the trappings of a major study, such as
randomization and hypothesis testing may be labeled a ‘‘pilot’’
because they do not have the power to test clinically meaningful
hypotheses. There are two major parametric assumptions, which
are routinely violated in pilot studies: sample size, and normal
distribution of the dependent variable. Although nonparametric
techniques do not require the stringent assumptions associated
with their parametric counterparts, this does not imply that they
are assumption free. CART analysis may be seen as an automatic
‘‘machine learning’’ method that produces a decision tree that can
be used for explorative purposes in studies with small sample size
Figure 5. A pruned version of the optimal trees.
doi:10.1371/journal.pone.0058768.g005
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within each cluster and allows to group subjects into more
homogeneous groups, using combinations of variables.
Materials and Methods
Sample Description
Ten Acute Infections (AI), 7 HAART treated patients
(HAART+), 7 AIDS patients at terminal stage of the diseases
(AIDS) naive for antiretroviral drugs, 10 Long Term Non
Progressors (LTNP), 8 Elite Controllers (EC), as shown in
Table 1. The inclusion criteria for LTNP were: 1. certified HIV-
1 seroconversion at least 7 years before enrollment; 2. asymptom-
atic HIV-1 infection and good health conditions; 3. peripheral
CD4+ T cell counts always .500 cells/mm3; 4. never receiving
antiretroviral therapy [22]. EC were defined as HIV-1 infected
patients able to exert spontaneous control of viremia for at least 2
consecutive years in the absence of HAART and viral load
persistently ,37 copies/mL [23]. HAART+ patients had CD4
counts .500 cells/mm3 on antiretroviral treatment for at least 24
and not more than 30 months with chronic and progressive
infection, but without previous AIDS defining disease. The similar
length of time of suppressive therapy in HAART treated patients
has been chosen in order to minimize possible differences in
immune status. AIDS patients exhibited one or more AIDS
defining diseases and CD4+ T cell counts ,250 cells/mm3 (these
patients were recruited between 1985–1993, before HAART era,
and they died after enrollment). In regard to AI, the eligible
patients had to fulfill at least one clinical criterion (signs and
symptoms of acute retroviral syndrome-ARS; signs and/or
symptoms of ARS during the previous 60 days; exposure to
HIV in the previous three months and a negative test in the
previous six months) and one laboratory criterion (detectable
plasma HIV-RNA; only gp120, gp1606p24 bands at Western
blotting; a low positive ELISA with increasing reactivity over
time). The AI population was analyzed at the onset of disease and
six months after receiving antiretroviral therapy. No statistical
differences were found for sex and age among the different
populations. Table 1 summarizes the clinical status of the study
populations.
Pooled sera from 10 Healthy-Controls (HC) not exposed to HIV
were used as negative controls in all assays.
All studied populations were recruited at the Department of
Infectious Diseases of the San Raffaele Scientific Institute or at the
Infectious Disease Clinic of the University of Milan at L. Sacco
Hospital.
The institutional review board and the local ethic committee of
San Raffaele Scientific Institute named ‘‘Comitato Etico della
Fondazione Centro San Raffaele del Monte Tabor-Istituto
Scientifico Ospedale San Raffaele’’ and of University of Milan
named ‘‘Comitato Etico Locale per la Sperimentazione Clinica
dell’Azienda Ospedaliera Luigi Sacco di Milano’’ approved the
investigations and all subjects gave written informed consent for
the study.
Quantification of Immunoglobulins
Total IgA and IgG in all serum samples were measured with
ELISA. Briefly, ELISA plates were coated with a 1:2000 dilution
of a goat anti-human IgA or IgG (100 ul/well) in coating buffer
and incubated for 1 h at 37uC. After washing, blocking buffer (1%
Skim Milk in Phosphate Buffer, Sigma) was added and plates were
incubated for 1 h at 37uC. Serial dilutions of samples and IgA or
IgG reference standards (Sigma) were incubated for 1 h at 37uC.
After washing, Goat anti-human IgA-Biotin (diluted 1:5000) or
Goat anti-human IgG-Biotin conjugate diluted 1:2000 (KPL) was
added and incubated 1 h at room temperature. Then, Streptavi-
din-HRP conjugate (Vector Laboratory) diluted 1:3000 was
incubated for 1 h at room temperature. TMB substrate (KPL)
was incubated for 5 minutes at room temperature in the dark.
Then 10% H2SO4 was added and plates were read out with a
spectrophotometer at 450 nm. Total IgA or IgG concentrations
were determined by interpolation, using the calibration line of IgA
or IgG reference standards, respectively.
Binding of Immunoglobulins to Recombinant env
Proteins and Peptides
The immunoglobulin fractions were tested in sandwich ELISA
to identify binding antibodies to env proteins, as previously
described [24–26]. The recombinant proteins gp120Bal and
gp120IIIB (obtained through the NIBSC, Programme EVA
Centre for AIDS Reagents, UK) and the gp41-specific peptides,
shown in Table 2 were used. Microwell plates were coated with
recombinant proteins (gp120 Bal and gp120 IIIB obtained
through the NIBSC, Programme EVA Centre for AIDS Reagents,
UK) and gp41-specific peptides (Table 2) at 1 mg/mL by means of
overnight incubation in NaHCO3/Na2CO3 buffer. The plates
were saturated for 1 h with PBS and 3% bovine serum albumin.
The eluted Igs were added and incubated for 1 h at 37uC. Ig
binding was demonstrated by means of HRP-conjugated rabbit
anti-human IgG and IgA (Dako, Santa Barbara, California, USA).
The enzymatic reaction was developed and read at 492 nm. The
endpoint titers were defined as twice the optical density (O.D.)
obtained in 20 seronegative control subjects.
Virus Neutralization Assays
HIV-1 pseudovirus stocks were generated by co-transfection of
293-T cells with Env-expressing pCAGGS-based plasmids and a
backbone plasmid lacking Env (pNL4-3.Luc.R-E-) and titrated for
infectivity in TZM-bl and U87.CD4.CCR5 [9,10]. Co-transfec-
tion generates HIV-1 pseudoviruses that are able to infect cells
with a single round infection because the plasmids encode an
incomplete HIV-1 genome. Two genetically engineered cell lines,
TZM-bl and U87.CD4.CCR5 (NIH AIDS Reagent Program,
Germantown, MD) and six HIV-1 strains were used to assess the
in vitro neutralizing activity of all the samples. CCR5- and CD4-
transfected TZM.bl cell line, genetically engineered to express a
Tat-responsive luciferase reporter gene (JC53-bl, NISBC) was used
as target cell for HIV-1 neutralization assay, as previously
described [27,28]. Neutralizing activity of heat inactivated sera
was evaluated using a panel of five pseudoviruses (NIBSC,
Programme EVA Centre for AIDS Reagents, UK), including
three Clade B (QH0692, AC10 and PVO), one Clade C (ZM214)
and one lab strain (SF162). All sera were tested in another
neutralization assay, as previously reported [7,9,29]. Briefly,
U87.CD4.CCR5 cells (a genetically engineered cell line expressing
CD4 and CCR5 as well as the luciferase gene) and an HIV-1
envelope mutant that introduces a disulfide bridge between the
gp120 surface proteins and gp41 transmembrane protein (named
SOS-gp140) were used. The neutralizing activity is readout by the
reduction of luciferase gene expression after a single round of virus
infection. Luciferase gene expression is quantified by luminescence
and is directly proportional to the amount of virus infection.
Pseudovirus Production for TZM-bl System
Neutralizing activity of heat inactivated sera from immunized
animals was evaluated using a panel of five pseudoviruses
(obtained through the NIBSC, Programme EVA Centre for AIDS
Reagents, UK) including three Clade B (QH0692, AC10 and
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PVO), one Clade C (ZM214) and one lab strain (SF162), in a
standardized and validated single round infection assay. Stocks of
single-round infection HIV-1 Env pseudoviruses were produced
by cotransfecting 293T/17 cells with 2 mg of an HIV-1 rev/env
expression plasmid and 12 mg of an env-deficient HIV-1 backbone
plasmid (pSG3DEnv) using Lipofectamine transfection reagent
(Invitrogen). Pseudovirus-containing supernatant was harvested
24 h following transfection, clarified by centrifugation and filtered
through 0.45 mm filters, and single-use 1 mL aliquots were stored
at 280uC. The 50% tissue culture infectious dose (TCID50) for
each pseudovirus preparation was determined by infection of
TZM.bl cells as previously described [27].
Pseudovirus Production for U87.CD4.CCR5 System
A human immunodeficiency virus type 1 (HIV-1) envelope
mutant that introduces a disulfide bridge between the gp120
surface proteins and gp41 transmembrane protein (named SOS-
gp140) were used. Briefly, plasmid (pCAGGS) was used to express
membrane bound envelope (SOS-gp140) of the primary R5 isolate
Jr-FL. Vesicular stomatitis virus G (VSV-G) was used as a negative
control virus. Pseudoviruses were produced by transfection of
293T cells with pNL4-3-LUC.R-E- and Env expressing
pCAGGS-based plasmids. Single round infections were performed
using U87.CD4.CCR5, and luciferase activity was measured in
the culture supernatants. The SOS virus was incubated with
inhibitor for 1 h before being transferred to U87.CD4.CCR5 cells
for a further 2 h of incubation. Unbound virus was removed by
changing medium, and the culture was incubated for a further 1 h.
Cells were plated in a 96-well plate (36104 cells/well). After 1 h
incubation, the growth medium was replaced by fresh growth
medium again and the plate was incubated at 37uC for 3 days.
Then the plate was washed with PBS and Bright-Glo substrate was
added. The cells were allowed to lyse for 2 minutes, and then the
supernatant was transferred to a 96-well white plate and readout
in a luminometer to quantify the luciferase activity. TCID50
values were calculated according to the method of Reed and
Muench [29].
TZM.bl Neutralization Assay
CCR5- and CD4-transfected TZM.bl cell line (JC53-bl
obtained through the NIH AIDS Research and Reference
Reagent Program, USA) was used as target cell for HIV-1
neutralization assay, as previously described [27,28]. Briefly, 3-fold
serial dilutions of serum samples (starting from 1:10 dilution), were
plated in duplicate (96-well flat bottom plate) in 10% D-MEM
growth medium (100 mL/well). 200 TC ID50 of each pseudovirus
were added to each well in a volume of 50 mL and incubated for
1 h at 37uC. TZM.bl cells were then added (16104 cells/well in a
100 mL volume) in 10% D-MEM growth medium containing
DEAE-dextran (Sigma Aldrich) at a final concentration of 11 mg/
mL. Assay controls included replicate wells of TZM.bl cells alone
(cell control) and TZM.bl cells with virus (virus control). Following
a 48 h incubation at 37uC, 150 mL of culture medium were
removed from each well and replaced with 100 mL of Bright-Glo
luciferase reagent (Promega). After 2 minutes incubation, 150 mL
of the cell lysate was transferred to a 96-well black solid plate and
luminescence was measured using a Victor Light 2030 luminom-
eter (Perkin Elmer). The 50% inhibitory dose (IC50) was
calculated as the serum dilution that induced a 50% reduction
in relative luminescence units (RLU) compared to the virus control
wells, after subtraction of cell control RLU. A pool of 2F5, b12
and 2G12 neutralizing monoclonal antibodies (TRIMAB) was
used at 7.4, 2.5, 0.82 and 0.27 mg/mL, as positive control. A pool
of 10 non HIV-related human sera was used as negative control.
Results are shown as % of infectivity reduction per each serum
after subtracting values observed with pool of pre-immune sera.
U87.CD4.CCR5 Neutralization Assay
All samples were also tested in another neutralization assay, as
previously reported [7,9,29]. Briefly, U87.CD4.CCR5 cells were
coated in 96-well plates and incubated at 37uC overnight. Serial
dilutions of test samples and positive control (MAb 2F5) were
prepared in 96-wells plate in triplicate. Three wells for respectively
background control and virus control were reserved. The
pseudovirus stock JFRL-140WT was diluted in growth medium
to a concentration giving 100,000–200,000 CPS, corresponding
with 10–30 TCID50/well, and was added to the diluted sample
containing wells. After incubation for 1 h, virus-sample mixtures
were added to the cell coated plate and incubated at 37uC for 3
days. After washing the cells with PBS, Bright-Glo substrate was
added. The cells were allowed to lyse for 2 minutes, and then the
supernatant was transferred to a 96-well white plate and readout
in a luminometer to quantify the luciferase activity. The
percentage of HIV-1 neutralization was calculated as the ratio of
CPS of the diluted test samples and CPS of the virus control wells
and multiplying by 100 and subtracting the result from 100.
Neutralization activities are expressed as the sample concentration
or dilution required to reduce the CPS by 50% (IC50).
Antibody Dependent Cellular Cytotoxicity Assay (ADCC
Activity)
ADCC tests were performed as described [30], using CEM-
NKr cells coated with each gp41 antiserum, as target cells. NKr-
CEM expressing CCR5 and THP1, were obtained from the NIH,
AIDS Research and Reference Reagent Program, Germantown,
USA. ADCC was performed using a rapid fluorescent-based assay,
as described in Guyre et al. [31].
Briefly, target cells at 36106 cells/mL were dually stained with
the cytosolic dye CFSE: 5-(and -6-) carboxyfluorescein diacetate
succinimidyl ester (Molecular Probes, Eugene, Oregon) at 1mM
and with the membrane dye PKH-26 (Sigma, St. Louis, MO) at
1mM for 5 minutes at 37uC. After dual staining, target cells were
incubated with the antibodies (serum samples at the indicated
dilution, or 2F5IgG as positive control) for 30 minutes at room
temperature. Effector cells, THP1, were then added at an
Effector:Target (E:T) ratio of 10:1. When indicated, cells were
incubated with irrelevant IgG for 15 minutes prior to their
addition in the ADCC reaction. Then, cell co-cultures were
centrifuged for 1 minute at 1000 rpm and incubated for 4 h at
37uC. When infected cells were used as targets, they were fixed
with 4% paraformaldehyde. Fluorescence profiles of the cell co-
cultures were immediately acquired using a Becton Dickinson
FACSCalibur. Data analysis was performed using Cytomics RXP
software. Flow cytometry dot plot of dual-stained target cells
incubated in the same conditions as the effector-target co-cultures,
was used to set the gate of living double positive target cells, where
the cell membrane was still intact. ADCC was calculated as
follows: (% of PKH-26high CFSE negative cells)/(% of PKH-26high
CFSE negative cells)+(% of PKH-26high CFSE high cells)6100.
When HIV-infected cells were used as target, the ADCC was
corrected by the actual amount of HIV-1 infected cells present at
the beginning of the assay, as determined by intra-cellular p24
labeling (as indicated above). Percent of ADCC lysis was estimated
as the difference in amount killing in presence and absence of a
given antibody. Positive control was gp41-specific IgG 98.6
resulting in .22% (SD: +/23) and specific cell lysis at 100 ng/
mL. Titer was defined as the lowest serum dilution or IgG
concentration inducing a specific cell lysis .10% [30].
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Statistics
In the preprocessing data phase, final endpoints were consid-
ered as continuous, whenever quantitative measurements were
taken on a continuous scale, or as categorical endpoints whenever
the variables were collapsing on non-continuous values (such as
presenting lots of zeros and few measurements different from zero).
In this case, dummy variables (0–1 variables) were defined as equal
to 1 if the variable takes values different from 0 and 0 if the
variable was exactly equal to 0. The different nature of the
variables required different statistical tools. Moreover, we used in
the analysis some ‘‘ratio responses’’ obtained by normalizing raw
values of continuous variables over the total of the immune
response (named ‘‘Ratio_name of the antibody’’).
In general, a nonparametric approach was chosen to allow for
small sample size. Figure 2 provides a graphical representation of
non-continuous variables, i.e. parameters found in some subjects
or groups only. In Figure 2 graphical representations of antibody
concentrations and ratios of antibodies to total IgG or IgA.
Classification and Regression Trees (CART) analysis was
performed to develop a clinical decision rule to classify HIV
patients on the basis of all the measurements, i.e. all the antibodies,
clinical endpoints and viruses. Percentage of correctly classified
patients provides a measure of accuracy of the derived rule.
CART analysis is a nonparametric and robust data-mining tool
that automatically searches for meaningful relationships among
variables, thus allowing to discover hidden patterns in complex
data and generating reliable predictive models [32].
A clear advantage of general nonparametric procedures over
commonly used parametric procedures is that underlying depen-
dence structures among biological variables can be modeled with
no need of stringent unrealistic assumptions.
Then, when included in a statistical model, interaction effects
involving more than two covariates can be difficult to interpret.
Moreover, in presence of categorical variables taking a large
number of values with few observations for each category,
convergence problems may occur. Finally, results provided by
traditional methods, such as standard multinomial logistic
regression, are commonly given in terms of probability and are
difficult to communicate to clinicians.
On the other hand, CART trees are data-driven methods easy
to interpret, even for non statisticians, and are characterized by
low computational complexity. Whenever available, a priori
information may be included in CART and may be integrated
with other pattern recognition algorithms (e.g., hidden Markov
models) [33].
CART analysis allows to construct decision trees useful in
classifying subjects into homogeneous groups on the basis of the
choice of optimal cut-points of binary, ordinal, or continuous
covariates, which maximizes a specific split criterion.
Due to its flexibility in handling complex multivariate/time
dependent data, this analysis is gaining popularity in clinical
research [34]. Some clear advantages of CART technique are: i)
no need of pre-selecting variables in advance. ii) CART algorithm
can identify the most significant variables and eliminate non-
significant ones. It is possible to test this property by including
insignificant (random) variable and compare newly generated tree
with the original one, built on initial dataset. iii) results are
preserved under monotone transformation of independent varia-
bles.iv) CART can easily handle outliers. Outliers in feasibility
studies represents a major hurdle. They can negatively affect the
results of many standard classification models, such as Principal
Component Analysis (PCA) and linear regression. However, these
problems can be overcome by CART analysis since, since its
algorithm isolates the outliers in a separate node. Actually, CART
can be applied for the identification of prognostic factors in many
classification problems.
Decision Trees: General Framework
Now we briefly introduce main ideas behind decision trees and
CART algorithms (displayed in Figure 6, A).
A decision tree is made up of nodes and leaves, with each leaf
denoting a class/group. Classes, commonly identified with groups
of patients relevant from a clinically point of view, are the outputs
of a tree.
Clinical endpoints collected throughout the study are the input
data.
Each branch of the tree ends in a terminal node and each
observation falls into exactly one terminal node. Each terminal
node is uniquely defined by a set of rules [8].
A tree has a root node (also called ‘‘top of the tree’’ or ‘‘first node’’)
whose descendant nodes (known as ‘‘daughters’’) can be divided into
terminal and split nodes. Leaf nodes, representing the last level of
nodes, contain the final classification. Intermediate nodes are
called ‘‘hidden’’ layers.
Input data consist of a response variable Y (e.g., an indicator
variables for patients) and a set of explanatory variables
X~(X1,X2, . . . ,Xk) with fixed dimensionality k, where Xi can
be continuous, categorical ordinal/non ordinal, possibly including
missing values.
A decision tree is generated according to the following
algorithm [8]. At each node, you should.
1. examine every allowable split on each predictor variable
(binary splits are generated by binary questions);
2. select and execute the ‘‘best’’ of the splits;
3. stop splitting on a node when some stopping rule is satisfied.
Binary trees, also chosen in our analysis, are the most popular
type of tree. In a binary tree, by convention if the answer to a
question is ‘‘yes’’, the left branch is selected. The same question
may appear more than one time in the network (see Figure 4).
To summarize, at each node, the tree algorithm searches
through the variables one by one, beginning with X1 and
continuing up to Xk. For each variable it finds the best split then
it compares the k best single variable splits and selects the best of
these. Steps 1 and 2 are then applied again to each of the daughter
nodes and so on thus arriving at the full tree.
In Step 2, to select the ‘‘best’’ split, criteria based on indexes of
entropy are commonly applied.
With reference to Step 3, in every recursive algorithm a
stopping criterion must be defined to get an informative good tree.
In the case of decision trees, it is crucial to decide when to stop
trying to split nodes.
If not stopped, the tree algorithm will extract all the information
from the data, so that resulting tree will fit random error or noise
instead of describing underlying relationships among variables. A
standard solution to this problem is to stop generating new split
nodes when subsequent splits only result in very little overall
improvement of the prediction.
Usually, splitting stops when each child nodes would contain
less than five data points, or when splitting increases the
information by less than some threshold.
One of the main drawbacks of decision trees is overfitting. In
many situations, tree tends to grow too big and have too few data
points in each terminal node to make the study worthwhile. To
overcome overfitting problem, trees are then recursively pruned.
For details on different pruning methods, see Breiman et al. (1984)
[8].
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Figure 6. CART toy example. Classification And Regression Trees (CART) are binary decision trees, attempting to classify a pattern by selecting
from a large number of variables the most important ones in determining the outcome variable. A decision tree consists of nodes and leaves, with
each leaf denoting a class. In a binary tree, by convention if the answer to a question is ‘‘yes’’, then the left branch is selected and the same question
may appear in more than one places in the tree. For example, attributes such as ‘‘Unprotected sexual activity’’, ‘‘More sexual intercourses’’, ‘‘Blood
transfusions (before 1985)’’ and ‘‘Being vaccinated against hepatitis A and/or hepatitis B’’ can be used to classify people as ‘‘L’’, low risk of getting
infected with HIV and ‘‘H’’, high risk of getting infected with HIV. Classes (low and high risk of getting infected with HIV) are the outputs of the tree.
Attributes (unprotected sexual activity, more sexual intercourses, possible blood transfusions (before 1985) and vaccine against hepatitis A and/or B)
are a set of features that describe the data. The input data consists of values of the different attributes. Using these attribute values, the decision tree
generates a class as the output for each input data. The top of the tree, or first node, is called the root node, intermediate nodes are the descendant
or ‘‘hidden’’ layers and the last level of nodes are the leaf nodes, that contain the final classification.
doi:10.1371/journal.pone.0058768.g006
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CART Analysis
The CART methodology is known as binary (i.e., parent nodes
are always split into exactly two child nodes) and recursive (i.e., the
process can be repeated by treating each child node as a parent)
partitioning [35]. The standard criterion used in CART to get the
best split to differentiate observations based on the dependent
variable is the Gini rule, i.e., a measure of how well the splitting
rule separates the classes contained in the parent node.
Variables are not selected in advance: CART algorithm is able
to recognize the most significant variables and eliminate the non
significant ones.
Of course, as mentioned in the previous section, when
constructing a tree, crucial steps include deciding how to grow
the tree, how to stop growing, and how to prune the tree to
increase generalization [8]. Once the tree building algorithm has
stopped, it is always useful to further evaluate the quality of the
prediction of the current tree in samples of observations that did
not participate in the original computations, applying for example
cross-validation and V-fold cross-validation approaches. These
methods are used to ‘‘prune back’’ the tree, i.e., to select a simpler
tree, equally accurate for predicting or classifying ‘‘new’’
observations. To summarize, there are three important aspects
in the construction of a tree [8,36].
1. Split selection rule: at each node, choose split maximizing
decrease in impurity (e.g. Gini index, entropy, misclassification
error).
2. Split-stopping rule: grow large tree, prune to obtain a sequence
of subtrees, then use cross-validation to identify the subtree
with lowest misclassification rate.
3. Class assignment rule: for each terminal node, choose the class
with the majority vote.
CART analysis is a powerful nonparametric and robust
technique with significant potential and clinical utility. It is
intended to identify distinct population subgroups and cannot
provide the estimation of net effects of a single independent
variable [37]. For the latter purpose, logistic regression techniques
have been widely used, in order to estimate the ‘‘average’’ effect of
an independent variable on the probability of being in a certain
group, given also a set of other factors. Hence, if the purpose of the
analysis is to quantify the influence of covariates on the outcome,
CART analysis is not an adequate tool and regression techniques
should be preferred in this type of situation. A toy example is
shown in Figure 6, B.
Supporting Information
File S1 Figure S1 and Table S1. Figure S1, ‘‘plotcp’’ function
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